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Abstract
Background: Magnetic resonance imaging (MRI) has the potential to help the surgeon
tailor radical prostatectomy (RP)more accurately according to the location and extent of
the tumour and thereby reduce the rate of positive surgical margins (PSMs).
Objective: To evaluate the beneﬁt of performing MRI prior to RP.
Design, setting, and participants: This single-institution randomised trial included
438 patients between December 2009 and June 2012 who were scheduled for robot-
assisted laparoscopic prostatectomy. The study was registered (ClinicalTrials.gov iden-
tiﬁer NCT01347320).
Intervention: Patientswerepreoperatively randomly assigned tonon-MRIorMRI groups.
Outcome measurements and statistical analysis: The primary end point was the differ-
ence in the PSM rates between the two groups. Secondary end points were the rates
of PSMs in clinical subgroups. Summary statistics were extracted from descriptive
analyses, chi-square, or Fisher exact test, and logistic regression was used to analyse
the data according to the intention-to-treat principle.
Results and limitations: A total of 216 patients were randomised to non-MRI; 222 were
randomised to MRI. There were 49 cases (23%) of PSMs in the non-MRI group and
43 cases (19%) in the MRI group (p = 0.4). The relative and absolute risk reduction was
15% and 4%, respectively. Patients with cT1 constituted 55% of the cohort, in which the
rate of PSMs was 27% in the non-MRI group and 16% in the MRI group (p = 0.035). The
relative and absolute risk reduction was 41% and 11%, respectively. A limitation was
suboptimal communication between the radiologist and urologist.
Conclusions: MRI prior to RP did not reduce the overall risk for PSMs in this patient
cohort. However, at subgroup analysis we observed a possible beneﬁt of MRI in patients
with cT1.
Patient summary: This study could not demonstrate a deﬁnite beneﬁt of performing
magnetic resonance imaging before surgery for all patients. However, there was a
possible improved result in patients in which physical examination could not detect
the cancer.
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Table 1 – Baseline characteristics of 438 patients randomized to
the non–magnetic resonance imaging (MRI) or MRI groups
Non-MRI (n = 216) MRI (n = 222)
Age, yr, mean  SD 63  6 62  6
PSA, ng/ml, median (IQR) 8.2 (6.2–18.3) 7.8 (4.9–11.3)
n % n %
cT stage
1c 114 53 125 56
2a 41 19 48 22
2b 41 19 25 11
2c 14 6.5 14 6.3
3a 6 2.8 10 4.5
Gleason score in biopsy
6 79 37 70 32
7a 79 37 89 40
7b 20 9.3 27 11
8 37 17 28 12
9 1 0.5 8 3.6
D’Amico risk groups
Low 55 25 57 26
Medium 103 48 114 51
High 58 27 51 23
IQR = interquartile range; MRI = magnetic resonance imaging; PSA =
prostate-speciﬁc antigen; SD = standard deviation.
E U RO P E AN URO LOG Y 6 8 ( 2 0 1 5 ) 4 8 7 – 4 9 64881. Introduction
The role of magnetic resonance imaging (MRI) before
radical prostatectomy (RP) is still under discussion, and
routine MRI is not considered mandatory [1]. No random-
ised controlled trials (RCTs) have been conducted to
evaluate the role of MRI prior to RP.
Ideally, MRI should detect all significant cancer foci and
give an accurate T classification for optimal surgical
planning. Studies have demonstrated a 80–94% detection
rate for the clinically dominant tumour, the so-called index
tumour [2–4]. The index tumour is associated with
extraprostatic extension (EPE) when relevant, the highest
Gleason score (GS), or the largest volume, in that order of
priority [5–7]. When present, the secondary and tertiary
tumour is the two next highest ranking tumours according
to the same criteria. The sensitivity of MRI for predicting
T3 is limited, ranging from13% to 95%, depending on patient
selection and the method used [8,9]. The laterality of T3 is
rarely reported, although it is highly relevant when
planning treatment [5,10].
Preoperative detection of T3 disease is clinically impor-
tant because T3 increases the risk of positive surgical
margins (PSMs), that is, cancer present on the surface of the
surgically removed prostate gland. PSMs are an indicator of
nonradical surgery and therefore an important parameter
when assessing the surgical quality of RP [11].
The aimof this RCTwas to assess the ability ofMRI before
RP to reduce the rate of PSMs.
2. Patients and methods
2.1. Setting
This single-institution RCT was approved by the local regional
committee for medical and health ethics (S-09143c2009/2183) and
registered at ClinicalTrial.gov (NCT01347320). All patients signed a
letter of consent.
2.2. Study design
All patients scheduled for robot-assisted laparoscopic prostatectomy
(RALP) at Oslo University Hospital, Aker, from December 1, 2009, to June
31, 2012, were candidates for the trial. Table 1 displays the baseline data
of the patient cohort. During the study period, 675 patients were
scheduled for RALP; 485 met the inclusion criteria, and 438 (90%) were
included for intention-to-treat analyses (Fig. 1).
2.3. Exclusion criteria
Exclusion criteria were previous relevant MRI of the prostate, contra-
indications to MRI, and hip prosthesis.
2.4. Randomisation
Allocation (1:1) of patients to either non-MRI or MRI was based on a
permuted block randomisation procedure with undisclosed and variable
blocking factor. After consent was received, each patient was designated
a unique, unchangeable sequentially numbered randomisation number,
matching an opaque and sealed envelope, containing the corresponding
intervention code (eg, non-MRI or MRI). It was not possible to replaceone envelope with another, and the envelope was disposed of after each
allocation. A logbook registered every procedure and was controlled
several times by the responsible statistician. The envelopes were
prepared by the centre of Biostatistics and Epidemiology, Research
Support Service, at Oslo University Hospital and kept accessible only to
E.R., who also performed the randomisation. Patients were scheduled for
MRI within 2 wk.
2.5. Sample size estimation
The rate of PSMs is highly associatedwith the incidence of pT3, andwhen
planning the study, the incidence of pT3was approximately 45%. For that
reason, we expected the rate of PSMs in the non-MRI group to lie
between 35% and 40%. A 20% difference in the rate of PSMs between the
non-MRI and MRI groups was considered clinically relevant. With a
signiﬁcance level of 0.05, 91–151 in each group was required to provide
80% power with a two-tailed test for two independent proportions,
assuming no dropout.
2.6. Magnetic resonance imaging
The MRI radiologist had 2 yr of experience with prostate imaging at the
start of the study. The radiologist was not systematically blinded to
prostate-speciﬁc antigen (PSA), cT stage, and GS. All patients in the MRI
group underwent 1.5-T MRI (Siemens, Erlangen, Germany) and six-
channel body matrix (Siemens). The time between biopsy and MRI was
11  7 wk (mean plus or minus standard deviation; range: 0–71) and
between MRI and surgery was 1  4 wk (range: 0–25). No patients were
excluded due to haemorrhagic artefacts or poor quality of the MRI.
The sequences included 0.9-mm isotropic three-dimensional T2 and
axial diffusion-weighted images (DWIs) using b50, b1000, and b2000. An
apparent diffusion coefﬁcient map was prepared from b50 and b1000.
The MRI acquisition and postprocessing were previously reported in
detail [12]. We used criteria for tumour detection and staging as
previously speciﬁed [2,5,13–16]. Both T2 and DWI were used for
detection and staging.
All patients also underwent axial and coronal T1-weighted imaging
of the pelvis and the lumbosacral spine to evaluate possible lymph node
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Number of patients referred to 
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Excluded  (n = 189) 
Previously performed MRI (112) 
Contraindications to MRI (23) 
Did not wish to participate (10) 
Treated at other hospital (9) 
Unknown (35) 
Patients included for intention-to-treat analysis
   (n = 222) 
Underwent MRI (203) 
Did not undergo MRI (19) 
Contraindications to MRI (5) 
Change in surgical date (6) 
Did not meet (3) 
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Underwent MRI (2) 
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Referred to MRI and rebiopsy
Did not undergo MRI (214) 
Allocation
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Withdrawn consent (8) 
No surgery was performed 
Skeletal metastases on MRI (4) 
Referred to radiation therapy (1) 
Cancelled surgery (9) 
Underwent surgery in another 
country  (1) 
Fig. 1 – Trial profile using the Consolidated Standards of Reporting Trials 2010 guidelines [1_TD$DIFF].
MRI = magnetic resonance imaging; RALP = robot-assisted laparoscopic prostatectomy.
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The MRI examination was completed within 20 min.
2.7. Communication with urologists prior to surgery
A schematic tumour map displaying the location and extent of the
tumours (indicated in red), including possible EPE and seminal vesicle
invasion, was drawn manually for every patient (Fig. 2) and shown to
the surgeon before surgery in each case. In addition, theMRI information
was registered in the electronic patient record system. Postoperatively,
the surgeon completed a form, in which he reported whether, and in
what way, MRI had changed the surgical approach.
2.8. Surgery
RALP was limited to four experienced urologists at the department.
The urologists had performed an average of 103 RALP procedures (range:
78–165), and a total of 415 laparoscopic prostatectomies (range:
296–585) at the start of the study.
Figure 2 illustrates the possible approaches for the surgical dissection.
The operations were classiﬁed as bilateral nerve-sparing surgery (BNS),
unilateral nerve-sparing surgery (UNS), or non–nerve-sparing surgery
(NNS). Nerve-sparing surgery included both intra- and interfascial
dissection, as described by Walz et al [10]. The NNS could be performedas a standard bilateral extrafascial dissection or as an extended excision.
The operator registered (1) the surgical plan before knowing the MRI
results, (2) the surgical plan after knowing the MRI, and (3) the means by
which the surgery actually was performed. We did not register whether
MRI resulted in more extensive surgery anteriorly or at the bladder neck.
The planned surgical approach was based on the preoperative
parameters available that included transurethral ultrasound (TRUS),
digital rectal examination (DRE), GS, tumour extent in biopsies, and
patient’s wish. When available, MRI was also taken into consideration.
2.9. Pathologic preparation and examination
Whole-mounted histologic sectionswere used as the reference standard.
Specimen handling was previously described in detail [2]. The surgical
margins were classiﬁed as positive when cancer tissue was present on
the inked surface of the prostate specimen. The sector associated with
each PSM was registered on a tumour map (Fig. 3). If a speciﬁc tumour
affected the same sector as the site of the PSM, it was classiﬁed as
responsible for the PSM. Each tumour and sector associated with PSMs
was classiﬁed as detected by MRI or not.
2.10. Clinical, radiologic, and pathologic T classification
The staging results of the clinical examination and MRI were previously
reported in detail [5] and are only brieﬂy reported in Table 2.
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Fig. 2 – The 30-sector tumour map used for registration of all tumours at magnetic resonance imaging and histology served as the basis for correlation
analysis. All suspected tumours were marked in red, and any extraprostatic extension was indicated. The map was then presented to the surgeon before
surgery. The three possible planes of dissection are indicated with stippled lines. Extended and non–nerve-sparing surgery was combined for statistical
analyses[5_TD$DIFF]. Figure adapted by Kari C. Toverud from Girouin et al. Eur Radiol. 2007;17:1498–509, with permission from Springer.# Kari C. Toverud.
Ant. = anterior; lat. = lateral; med. = medial; NVB = neurovascular bundle; Post. = posterior.
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patients as having clinically localised (cT1c or cT2a–c) or nonlocalised
disease (cT3a–b). Due to a low number of cT3a–b cases, these patients
were combined with cT2a–c in the statistical analyses. Correspondingly,
MRI (rT) and histopathology (pT) classiﬁed all patients as localised (T2)
or nonlocalised (T3).
2.11. Statistical analyses
The rate of PSMs in the non-MRI and MRI groups was the primary end
point. Clinical subgroups were deﬁned according to the T classiﬁcation,
D’Amico risk groups, GS, and surgical procedures.
The Pearson chi-square or Fisher exact test assessed differences in
the rate of PSMs between the non-MRI and MRI groups and in clinical
subgroups.
The proportions of PSMs and odds ratios (ORs) with 95% conﬁdence
intervals (CIs) were used to describe the differences. Both absolute and
relative differences (risk ratio) are reported.
Differences in the ORs of the clinical subgroups were examined by
the interaction term between the non-MRI and MRI group variable and
the clinical subgroup variable using logistic regression. All analyses
were performed according to the intention-to-treat principle. Two-sided
p values were given and not corrected for multiple testing.
IBM SPSS Statistics v.22 (IBM Corp., Armonk NY, USA) and MedCalc
statistical software v.14.8.1 (MedCalc Software, Ostend, Belgium) were
used for statistical analyses.3. Results
A total of 438 patients were included in this study, in which
216 were randomised to the non-MRI group and 222 were
randomised to theMRI group (Fig. 1). Table 1 shows that the
groups were well balanced.
3.1. Magnetic resonance imaging tumour detection results
MRI tumour detection rates and staging results of this
cohort were reported in two previous papers and are only
mentioned briefly [2,5]. MRI detected 92% of the index
tumour; it did not detect the index tumour in 16 patients.
However, in 5 of these 16, MRI detected the second largest
tumourwith identical GS as the index tumour. In 11 patients
with specimen GS 6 and 7, no tumour was found on MRI.
3.2. Surgical procedures
Thesurgeons reported thatMRI altered the surgicalprocedure
on one or both sides in 59 patients (27%), of which 30 (51%)
were cT1, 29 (49%) were cT2, and 49 (83%) were rT3. All
changeswere in thedirectionof amore radical excision. There
was no difference in mean age, PSA, and GS in biopsy of
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nonadjusted surgery. BNSwas performed in 35 of 90 patients
(39%) classified as rT2 versus 15 of 110 (14%) for rT3
(p< 0.001).
The overall rate of BNS, UNS, and NNS was 30%, 34%, and
35%, respectively. The absolute rate of BNSwas 6.7% (95% CI,
2 to 16; p = 0.12) lower in the MRI group compared withTable 2 – The performance of magnetic resonance imaging and
digital rectal examination/transrectal ultrasound for detecting pT3
disease
Sensitivity, % (95% CI) Speciﬁcity, % (95% CI)
MRI
All patients 73 (63–81) 65 (54–74)
cT1 56 (41–70) 70 (57–81)
cT2–3 88 (76–95) 55 (36–72)
DRE/TRUS 4 (2–8) 98 (95–99)
CI = conﬁdence interval; DRE/TRUS = digital rectal examination/transurethral
ultrasound; MRI = magnetic resonance imaging.the non-MRI group (Table 3). This difference was mainly
due to a 13% (95% CI, 1–25; p = 0.024) lower rate of BNS in
patients with cT2–3 (Fig. 4).
3.3. Overall risk of positive surgical margins
There were 49 cases (23%) of PSMs in the non-MRI group
and 43 (19%) in the MRI group (Table 4). The relative and
absolute reduction was 15% (0.85; 95% CI, 0.6–1.2) and 4%
(95% CI,4 to 10; p = 0.4), respectively. The number needed
to treat was 25, and two extra nerve resections (1.7%) were
performed for each PSM avoided.
3.4. Risk of positive surgical margins in patient subgroups
MRI did not reduce the rates of PSMs in cT2–3, whereas
in cT1, the relative and absolute reduction was 41% (0.59;
95% CI, 0.4–0.9) and 11% (95% CI, 2–22; p = 0.035),
respectively (Tables 3 and 4). There was no benefit of
MRI in any other subgroups.
Table 3 – Positive surgical margin rate with respect to surgical procedure, cT stage, and Gleason score in biopsy
Non-MRI (n = 216) MRI (n = 222)
Total PSM Total PSM
n % n % n % n % p p*
Bilateral nerve-sparing surgery
DRE 0.15
cT1 45 49 11 24 46 51 5 11 0.089
cT2–3 28 67 2 7.1 14 33 2 14 0.5
Gleason score in biopsy 0.6
6 34 53 7 21 30 47 2 7 0.11
7a 26 54 3 12 22 46 5 23 0.3
7b 8 62 2 25 5 38 0 0 0.2
8 5 63 1 20 3 34 0 0 0.4
9 NA NA NA 0 NA NA NA
All patients 73 33 13 18 60 25 7 12 0.3
Unilateral nerve-sparing surgery
DRE 0.9
cT1 29 42 6 21 40 58 7 16 0.7
cT2–3 42 51 9 21 40 49 7 19 0.7
Gleason score in biopsy 0.7
6 29 58 4 14 23 42 1 4 0.3
7a 26 43 7 27 35 57 8 23 0.7
7b 6 30 1 17 14 70 3 17 0.8
8 10 56 3 30 8 44 2 25 0.8
9
All patients 71 47 15 21 80 53 14 18 0.6
Non–nerve-sparing surgery
DRE 0.086
cT1 40 51 14 35 39 49 8 19 0.15
cT2–3 32 43 7 23 43 57 14 30 0.3
Gleason score in biopsy 0.7
6 16 48 3 19 17 52 2 12 0.6
7a 27 46 7 26 32 54 10 30 0.7
7b 6 40 3 50 9 60 5 50 0.8
8 22 58 8 36 16 42 3 19 0.2
9 1 11 0 0 8 89 2 25 0.6
All patients 72 47 21 29 82 53 22 27 0.7
DRE = digital rectal examination; MRI = magnetic resonance imaging; NA = not available; PSM = positive surgical margins.
* The p value for interaction.
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surgery were 25% and 17%, respectively (8% difference;
95% CI, 4 to 22; p = 0.17). Most patients with PSMs
underwent UNS or NNS; 36 of 49 (73%) in the non-MRI
group and 36 of 43 (84%) in the MRI group (11% difference;
95% CI, 8 to 29; p = 0.2). For patients classified as rT3, the
rate of PSMs was 25%; 89% of these patients underwent
either UNS or NNS (Fig. 5).
3.5. Distribution of positive surgical margins and the
associated tumour
There were 126 sites of PSMs in 92 specimens (Fig. 6). Sixty
patients had a single PSM site; 32 had more than one. The
index tumourwas the responsible tumour in 89% of all cases
of PSMs, and 60% were associated with EPE at the same
location.
MRI detected 92% of all tumours related to PSMs. The
base and apex were at higher risk for PSMs (Fig. 3). The risk
of ventral PSMs in the apex was higher in the non-MRI
group (12%; 95% CI, 3 to 23; p = 0.072).4. Discussion
The present study is the first RCT to evaluate the benefit of
MRI prior to RALP. We could not demonstrate a significant
reduction in the rate of PSMs for either the whole cohort or
patients with pT3. However, we found a 41% lower rate of
PSMs in patients with cT1 (p = 0.035), although this was not
statistically significant in the context of multiple testing.
The rate of PSMs varies significantly in the literature, and
our results are within acceptable limits [17,18].
4.1. Effect of magnetic resonance imaging on surgical approach
MRI changed the surgical strategy in 29%, all in the direction
of more radical excision. Other studies have reported
that MRI affected the surgery in a radical direction in only
33–39% [19–21]. None of these studies had a control arm
without MRI, making comparison difficult.
Most of the patients with PSMs had undergone UNS or
NNS in both the non-MRI and MRI group. Also, when MRI
suggested T3, 89% of those with PSMs had undergone either
[(Fig._4)TD$FIG]
Fig. 4 – In patients with cT1, the relative risk of positive surgical margins
(PSMs) was 41% lower in the magnetic resonance imaging (MRI) group,
and there was a reduction in PSMs regardless of the surgical procedure.
There was no significant difference in the surgery between the two
groups. Unexpectedly, in patients with cT2–3, the overall PSM rate
increased by 6% (95% confidence interval, S6 to 18; p = 0.4) in the MRI
group, despite the fact that unilateral nerve-sparing surgery and non–
nerve-sparing surgery were performed 13% more frequently in the MRI
group.
BNS = bilateral nerve-sparing surgery; MRI = magnetic resonance
imaging; NNS = non–nerve-sparing surgery; PSM = positive surgical
margins; UNS = unilateral nerve-sparing surgery.
Table 4 – Rate of positive surgical margins in the non–magnetic reson
Non-MRI (n = 216)
Total, n PSM, n % Total,
All patients 216 49 23 222
DRE
cT1 114 31 27 125
cT2–3 102 18 18 97
D’Amico risk classiﬁcation
Low 55 7 13 57
Medium 103 24 23 114
High 58 18 31 51
pT stage
2 111 9 8.1 103
3 105 40 38 119
Gleason score in specimen
6 59 9 15 57
7a 83 17 20 87
7b 44 11 25 48
8 23 9 39 22
9 7 3 43 8
CI = conﬁdence interval; DRE = digital rectal examination; MRI = magnetic resona
OR <1 indicates a reduced risk of positive surgical margins; OR >1 indicates an
* The p value for interaction: A signiﬁcant interaction p value indicates that the
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excisions are required to reduce the rate of PSMs.
4.2. Rate of positive surgical margins in patients with cT1
Surprisingly, the greatest benefit ofMRI was seen in patients
with cT1. Thiswas unexpected because the sensitivity ofMRI
for predicting pT3 in this group was poor (Table 2), and
surgical procedures were not significantly different between
the non-MRI and MRI group (Fig. 4). This suggests that the
primary value of MRI was to provide the surgeon with
accurate information about tumour location and extension,
whereas staging was of secondary importance.
4.3. Possible mechanisms for improved outcome in cT1
This study cannot explain the exact mechanisms for the
reduced rate of PSMs in patients with cT1. However, one
possibility may be excellent tumour visualisation on MRI,
also in patients with cT1, whereas DRE and TRUS are normal.
This probably favours selection of the proper surgical
procedure, and it may have prevented dissection too close
to the index tumour or changed the surgery in ways not
registered in this study. For instance, in case of a ventral
cancer with extraprostatic disease, it is possible to perform a
combination of BNS and extended excision ventrally.
4.4. Importance of the index tumour and positive surgical
margins site
The index tumourwas the source of PSMs in 89% of the cases
(Fig. 6). This illustrates the relevance of locating the index
tumour before surgery and is in accordance with a
2012 study [22]. However, despite the fact that MRI
detected 98% of these tumours, the rate of PSMs did not
improve for the whole cohort. If the MRI findings areance imaging (MRI) and MRI groups
MRI (n = 222)
n PSM, n % p OR 95% CI *p
43 19 0.4 0.81 0.5–1.3
0.029
20 16 0.035 0.51 0.3–0.9
23 24 0.3 1.53 0.7–2.9
0.8* 0.8
3 5.3 0.38 0.1–1.6
25 22 0.93 0.5–1.7
15 29 0.41 0.4–2.1
0.7* 0.7
5 4.9 0.58 0.2–1.8
38 32 0.76 0.4–1.3
0.8* 0.8
7 12 0.78 0.3–2.3
14 16 0.75 0.3–1.6
14 29 1.21 0.5–3.1
6 27 0.58 0.2–2.1
2 25 0.44 0.1–4.0
nce imaging; OR = odds ratio.
increased risk.
ORs of the subgroups are signiﬁcantly different.
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Fig. 6 – The associated tumour for each case of positive surgical margins (PSMs) and whether magnetic resonance imaging (MRI) detected it or not.
Also shown is whether the PSMs were associated with extraprostatic extension in the same area. MRI identified most tumours and sectors associated
with PSMs, suggesting that the surgeons did not sufficiently consider the MRI findings.
EPE = extraprostatic extension; MRI = magnetic resonance imaging; PSM = positive surgical margins.
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Fig. 5 – Bilateral nerve-sparing surgery was chosen in 15 of 110 patients (14%) when magnetic resonance imaging (MRI) suggested T3 disease. For
unknown reasons, the surgeon chose not to consider the MRI findings. Six of the patients turned out to have pT3 in which two had positive surgical
margins (PSMs); the remaining nine were pT2 and one had PSM. In 95 of 110 patients (86%), the surgical procedure harmonised to a larger extent with
the MRI finding; however, 24 of 27 patients (89%) with PSMs were found in this group. This illustrates that the degree of non–nerve-sparing excision
was not sufficient.
BNS = bilateral nerve-sparing surgery; MRI = magnetic resonance imaging; NNS = non–nerve-sparing surgery; NSM = negative surgical margins;
PSM = positive surgical margins; UNS = unilateral nerve-sparing surgery.
E U RO P E AN URO LOG Y 6 8 ( 2 0 1 5 ) 4 8 7 – 4 9 6494included in the planning of surgical approach to a larger
extent, it represents a considerable potential for improve-
ment in the future.
The MRI group experienced a lower rate of PSMs in the
ventral apex (Fig. 3), although the prognostic value of this is
controversial [23,24].
4.5. Magnetic resonance imaging protocol
This study used a simple MRI protocol, without contrast
medium and endorectal coil, compared with the currentEuropean Society of Urogenital Radiology recommendation
[25]. Nevertheless, we achieved similar detection and
staging results as those who have used the current
recommendation [2,4,5,26,27]. This may indicate that a
simple protocol is truly sufficient, although no studies have
compared the different protocols on the same cohort, and
direct comparison of results is difficult. Alternatively, our
high rate of large tumours with pT3 resulted in extraordi-
nary results.
From a surgical point of view, it is critical to stress that
MRI tumour detection is highly sensitive in most studies;
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urologists are encouraged to consider tumour locationmore
than rT classification when deciding surgical strategy.
4.6. Limitations
This study has some possible limitations. First, the study
was underpowered to demonstrate a significant effect of
MRI because the observed rate of PSMs was approximately
half of the expected rate. Because all subgroup analyses
were not defined a priori, one should interpret the findings
in cT1 with caution and instead conduct future studies.
Second, more patients were referred to radiation therapy in
the non-MRI group after randomisation. This may be an
indicator of more advanced disease, likely to result in PSMs.
Consequently, it may have reduced the effect of MRI. Third,
the radiologist was not fully blinded to clinical data. This
might have affected the MRI results and consequently
patient handling. Fourth, there was suboptimal communi-
cation between the radiologist and the urologist during this
study. This is probably the most important reason why the
difference in the rate of PSMs between the two groups was
not larger. We believe the radiologists and the urologist
should coinvestigate MRI images prior to surgery because
only reading a written report or looking at a schematic
drawing is suboptimal when planning surgery.
5. Conclusions
We showed that the index tumour, usually detected byMRI,
is the most frequent cause of PSMs. We did not find an
overall reduction in the rate of PSMs in patients randomised
to MRI, although subgroup analysis revealed a possible
benefit in patients with cT1. Our study suggests more
radical resection should be performed in the index tumour
region and that future studies should focus on MRI-guided
RP. In the MRI group, slightly more nerve resections were
performed, which can be considered a potential negative
effect ofMRI.More studies are needed to evaluate the role of
MRI before prostatectomy.
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